Skip to main content

Table 2 Treatment and prognosis of COVID-19 Patients with and Without Influenza IgM positive

From: Clinical characteristics and outcome of influenza virus infection among adults hospitalized with severe COVID-19: a retrospective cohort study from Wuhan, China

Study Population With influenza IgM positive (n = 73) Without influenza IgM positive (n = 67) Total (n = 140) P value
Treatment in hospital
 Oxygen Therapy
 Nasal Cannula 32 (43.8) 29 (43.3) 61 (43.6) 0.9475
 Oxygen Mask 1 (1.4) 2 (3.0) 3 (2.1) 0.5069
 NMV/High-flow nasal cannula 35 (47.9) 34 (50.7) 69 (49.3) 0.7405
 IMV/ECMO 7 (9.6) 5 (7.5) 12 (8.6) 0.6535
 Drugs
  Oseltamivir 33 (45.2) 23 (34.3) 56 (40.0) 0.1894
  Arbidol 53 (72.6) 47 (70.1) 100 (71.4) 0.7482
  Compound Methoxamine capsule 17 (23.3) 6 (9.0) 23 (16.4) 0.0222
Clinical outcomes
 CURB-65     0.0397
  Low risk 65 (89.0) 50 (74.6) 115 (82.1)
  Medium risk 6 (8.2) 8 (11.9) 14 (10.0)
  High risk 2 (2.7) 9 (13.4) 11 (7.9)
 Duration of viral shedding, days 26.0 (20.0, 32.0) 25.0 (21.0, 32.0) 25.5 (20.5, 32.0) 0.9694
 Hospital length of stay, days 13.0 (10.0, 18.0) 14.0 (10.0, 17.0) 13.0 (10.0, 18.0) 0.9084
 Time from illness onset to discharge, days 27.0 (22.0, 35.0) 27.0 (21.0, 33.0) 27.0 (22.0, 33.5) 0.6208
 Death,No (%)     0.0276
  Discharge 70 (95.9) 57 (85.1) 127 (90.7)
  Death 3 (4.1) 10 (14.9) 13 (9.3)